Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ROS1 fusion |
| Therapy | Zidesamtinib |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ROS1 fusion | lung non-small cell carcinoma | sensitive | Zidesamtinib | FDA approved | Actionable | In a Phase I trial (ARROS-1) that supported FDA approval, Jideytro (zidesamtinib) treatment demonstrated safety and activity in patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have received prior ROS1 TKI, resulting in an overall response rate (ORR) of 44% (51/117), duration of response rate of 84% at 6 mo, 78% at 12 mo, and 62% at 18 mo, with respective progression-free survival rate of 57%, 48%, and 40% (J Thor Oncol (2025) 20 (10, Suppl_1): S3; NCT05118789). | detail... detail... |
| ROS1 fusion | lung non-small cell carcinoma | sensitive | Zidesamtinib | Guideline | Actionable | Jideytro (zidesamtinib) is included in guidelines as subsequent therapy (category 2A) for patients with advanced or metastatic non-small lung cancer harboring a ROS1 fusion (NCCN.org). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| NCCN.org | Full reference... | |
| Jideytro (zidesamtinib) FDA Drug Label | Full reference... | |
| PL02.15 Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pre-treated Patients with Advanced/Metastatic ROS1+ NSCLC | Full reference... |